Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 10, Number 3—March 2004
Perspective

Clinical Trials and Novel Pathogens: Lessons Learned from SARS

Matthew P. Muller*‡, Allison McGeer*‡, Sharon E. Straus†‡, Laura Hawryluck†‡, and Wayne L. Gold†‡Comments to Author 
Author affiliations: *Mount Sinai Hospital, Toronto, Ontario, Canada; †University Health Network, Toronto, Ontario, Canada; ‡University of Toronto, Toronto, Canada

Main Article

Table

Eligible cases lost to enrollment in a hypothetical trial of ribavirin during the first outbreak of SARS in Toronto.

Date from outbreak recognition to date of enrollment of first patient (days) Number of cases lost to enrollment (%)
March 13–16 (3)
6/249 (2)
March 13–20 (7)
37/249 (15)
March 13–23 (10)
62/249 (25)
March 13–28 (15)a
114/249 (46)
March 13–31 (18)b 149/249 (60)

aApproval from first local ethics review board
bApproval from Health Canada

Main Article

Page created: February 08, 2011
Page updated: February 08, 2011
Page reviewed: February 08, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external